Health TrialsbyHealthPanel

To Investigate the Real-world Efficacy and Safety of Sacituzumab Govitecan for HER2 Negative Metastatic Breast Cancer Patients in China.

ConditionBreast Cancer Metastatic
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexFemale
Age18-75
SponsorZhejiang Cancer Hospital

About this trial

To investigate the real-world efficacy and safety of Sacituzumab govitecan for HER2 negative metastatic breast cancer patients in China.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

None

Disqualifiers

None

Trial population

Patient had a diagnosis of metastatic breast cancer, received at least two cycles of sacituzumab govitecan.

Trial design

Design model

Cohort

Time perspective

Prospective

Treatments tested in this trial

Not listed

Trial groups

No trial groups listed

Trial outcomes

Primary outcomes

1

PFS

Progression-Free Survival

Time frame
from enrollment to progression or death (for any reason),assessed up to 100 months

Secondary outcomes

1

Objective Response Rate

Ratio of CR and PR in all subjects

Time frame
from enrollment to progression or death (for any reason), assessed up to 100 months
2

DoR

Duration of Response

Time frame
The first evaluation of CR or PR to progression or death (for any reason),assessed up to 100 months
3

OS

Overall Survival

Time frame
from enrollment to death (for any reason).assessed up to 100 months

Other outcomes

1

adverse event

Adverse events are described in terms of CTC AE 5.0

Time frame
from enrollment to 30 days after the last dose administrate

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Zhejiang Cancer Hospital

Lead sponsor

Source ClinicalTrials.gov
Apply now